Imatinib enchances the sensitivity of gastrointestinal stromal tumors to topoisomerase II inhibitors
Objective: to study the sensitivity of gastrointestinal stromal tumors (GISTs) to the topoisomerases type II inhibitors and ability of imatinib to enhance GISTs sensitivity to the chemotherapeutic drugs indicated above.Subjects and Methods. We studied the sensitivity of gastrointestinal stromal tumo...
Main Authors: | S. V. Boichuk, A. R. Galembikova, B. R. Ramazanov, A. Duensing |
---|---|
Format: | Article |
Language: | Russian |
Published: |
ABV-press
2015-06-01
|
Series: | Успехи молекулярной онкологии |
Subjects: | |
Online Access: | https://umo.abvpress.ru/jour/article/view/7 |
Similar Items
-
CLINICAL EXPERIENCE IN USING TARGETED THERAPY FOR DISSEMINATED GASTROINTESTINAL STROMAL TUMORS
by: S. T. Adlejba, et al.
Published: (2019-06-01) -
Prospects of Chemotherapy for Gastrointestential Stromal Colon Tumours
by: A. R. Mukhamediyarov, et al.
Published: (2020-11-01) -
GASTROINTESTINAL STROMAL TUMORS: WHAT’S NEW IN THERAPY?
by: A. G. Kornilova, et al.
Published: (2016-02-01) -
Molecular features and genetic markers of gastrointestinal stromal tumors
by: N. N. Mazurenko, et al.
Published: (2015-06-01) -
Molecular heterogeneity and analysis of the long-term survival of patients with gastrointestinal stromal tumors
by: N. N. Mazurenko, et al.
Published: (2022-06-01)